The participant declined immunomodulatory therapy after consideration of its risks and benefits, and instead has used a continuous glucose monitoring (CGM) system, which she describes as life changing, continuing once daily biphasic insulin, injecting this up to 1.5 h before breakfast to try and minimise postprandial hyperglycaemia. The gene discussed is INS; the disease is Hyperglycemia.